GRAIL published a new episode of Doctors Making a Difference discussing multi-cancer early detection, including findings from the PATHFINDER 2 study and the NHS-Galleri trial.
Published
Signal category
Research & Knowledge
Quote
“The discussion explores the evolving evidence for MCED, including findings from the PATHFINDER 2 study and the NHS-Galleri trial”
— GRAIL team
Company
GRAIL
Detect cancer early, when it can be cured.
- Location
- Menlo Park, US
- Company size
- 1,139 employees
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. GRAIL is headquartered in Sunnyvale, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit grail.com. Community Guidelines: https://bit.ly/3xigb24